Path: /organizations/promis-neurosciences
Type: Biotechnology Company
Headquarters: Montreal, Quebec, Canada
Founded: 2010
Stock: TSX: PMN
ProMIS Neurosciences is a Canadian biotechnology company headquartered in Montreal, Quebec, focused on developing monoclonal antibodies for the treatment of neurodegenerative diseases. The company's proprietary platform targets toxic oligomers of misfolded proteins—a key pathological driver in both Alzheimer's and Parkinson's diseases.
ProMIS has developed a unique approach to targeting misfolded proteins. Unlike traditional antibodies that recognize mature fibrils or monomers, ProMIS antibodies selectively target toxic oligomers—the soluble, prefibrillar aggregates that are now recognized as the most pathogenic species in neurodegenerative diseases.
The company's platform identifies disease-specific conformational epitopes that are unique to oligomeric forms of proteins like amyloid-beta and alpha-synuclein, sparing normal protein function.
| Protein | Disease | Status |
|---|---|---|
| Amyloid-beta oligomers | Alzheimer's Disease | Preclinical |
| Alpha-synuclein oligomers | Parkinson's Disease | Research |
PMN310 is ProMIS's lead candidate for Alzheimer's disease, a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers while sparing monomers and fibrils. This approach may provide superior efficacy compared to existing antibodies that target all forms of amyloid-beta.
PMN250 targets toxic alpha-synuclein oligomers implicated in Parkinson's Disease and related synucleinopathies including Lewy Body Dementia and Multiple System Atrophy.
ProMIS's approach is based on:
The company holds patents covering its oligomer-selective antibody platform, including compositions of matter and methods of treatment for multiple neurodegenerative diseases.
ProMIS is led by an experienced team with expertise in antibody development, neurodegeneration biology, and pharmaceutical development.